Literature DB >> 29588321

Protumor Steering of Cancer Inflammation by p50 NF-κB Enhances Colorectal Cancer Progression.

Chiara Porta1, Alessandro Ippolito2, Francesca Maria Consonni2, Lorenzo Carraro2, Giuseppe Celesti3, Carmen Correale3, Fabio Grizzi3, Fabio Pasqualini3, Silvia Tartari3, Maurizio Rinaldi2, Paolo Bianchi3, Fiorella Balzac4, Stefania Vetrano3, Emilia Turco4, Emilio Hirsch4, Luigi Laghi3, Antonio Sica1,3.   

Abstract

Although tumor-associated macrophages (TAM) display a M2-skewed tumor-promoting phenotype in most cancers, in colorectal cancer, both TAM polarization and its impact remain controversial. We investigated the role of the M2-polarizing p50 NF-κB subunit in orchestrating TAM phenotype, tumor microenvironment composition, and colorectal cancer progression. We first demonstrated, by parallel studies in colitis-associated cancer (CAC) and in genetically driven ApcMin mouse models, that the p50-dependent inhibition of M1-polarized gut inflammation supported colorectal cancer development. In accordance with these studies, p50-/- mice displayed exacerbated CAC with fewer and smaller tumors, along with enhanced levels of M1/Th1 cytokines/chemokines, including IL12 and CXCL10, whose administration restrained CAC development in vivo The inflammatory profile supporting tumor resistance in colons from p50-/- tumor bearers correlated inversely with TAM load and positively with both recruitment of NK, NKT, CD8+ T cells and number of apoptotic tumor cells. In agreement, myeloid-specific ablation of p50 promoted tumor resistance in mice, whereas in colorectal cancer patients, a high number of p50+ TAMs at the invasive margin was associated with decreased IL12A and TBX21 expression and worse postsurgical outcome. Our findings point to p50 involvement in colorectal cancer development, through its engagement in the protumor activation of macrophages, and identify a candidate for prognostic and target therapeutic intervention. Cancer Immunol Res; 6(5); 578-93. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29588321     DOI: 10.1158/2326-6066.CIR-17-0036

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  22 in total

1.  Heme catabolism by tumor-associated macrophages controls metastasis formation.

Authors:  Francesca Maria Consonni; Augusto Bleve; Maria Grazia Totaro; Mariangela Storto; Paolo Kunderfranco; Alberto Termanini; Fabio Pasqualini; Chiara Alì; Chiara Pandolfo; Francesco Sgambelluri; Giulia Grazia; Mario Santinami; Andrea Maurichi; Massimo Milione; Marco Erreni; Andrea Doni; Marco Fabbri; Laura Gribaldo; Eliana Rulli; Miguel Parreira Soares; Valter Torri; Roberta Mortarini; Andrea Anichini; Antonio Sica
Journal:  Nat Immunol       Date:  2021-04-26       Impact factor: 25.606

2.  Phloretin Protects Bovine Rumen Epithelial Cells from LPS-Induced Injury.

Authors:  Kexin Wang; Qian Lei; Huimin Ma; Maocheng Jiang; Tianyu Yang; Qianbo Ma; Osmond Datsomor; Kang Zhan; Guoqi Zhao
Journal:  Toxins (Basel)       Date:  2022-05-11       Impact factor: 5.075

3.  Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells.

Authors:  Qiu-Ting Li; Meng-Jun Qiu; Sheng-Li Yang; Xiefan Fang; Xiao-Xiao He; Meng-Meng Wang; Ya-Nan Li; Zhi-Fan Xiong; Shanshan Huang
Journal:  J Oncol       Date:  2020-07-28       Impact factor: 4.375

4.  Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) impedes the growth of MHC-matched high-risk neuroblastoma.

Authors:  Cheng Cui; Theresa Barberi; Rahul Suresh; Alan D Friedman
Journal:  Mol Oncol       Date:  2021-05-02       Impact factor: 6.603

5.  RelB plays an oncogenic role and conveys chemo-resistance to DLD-1 colon cancer cells.

Authors:  Xiaojun Zhou; Zhili Shan; Hengying Yang; Jingjing Xu; Wenjing Li; Feng Guo
Journal:  Cancer Cell Int       Date:  2018-11-13       Impact factor: 5.722

6.  SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities.

Authors:  Sabina Sangaletti; Giovanna Talarico; Claudia Chiodoni; Barbara Cappetti; Laura Botti; Paola Portararo; Alessandro Gulino; Francesca Maria Consonni; Antonio Sica; Giovanni Randon; Massimo Di Nicola; Claudio Tripodo; Mario P Colombo
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

7.  LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1.

Authors:  Yang Bai; Chenchen Ren; Baojin Wang; Jingge Xue; Feiyan Li; Jiaxi Liu; Li Yang
Journal:  Cancer Gene Ther       Date:  2021-05-25       Impact factor: 5.987

Review 8.  NFKB1 and Cancer: Friend or Foe?

Authors:  Julia Concetti; Caroline L Wilson
Journal:  Cells       Date:  2018-09-07       Impact factor: 6.600

9.  The levels of NF-κB p50 and NF-κB p65 play a role in thyroid carcinoma malignancy in vivo.

Authors:  Fei Le; Jing-Yu Zhang; Wei Liu; Xian-Ming Huang; Wen-Zheng Luo
Journal:  J Int Med Res       Date:  2018-07-17       Impact factor: 1.671

10.  Knockdown of MON1B Exerts Anti-Tumor Effects in Colon Cancer In Vitro.

Authors:  Lai Jiang; Jun Qian; Yongbo Yang; Yongtian Fan
Journal:  Med Sci Monit       Date:  2018-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.